Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06693336 · ClinicalTrials.gov registry record · Phase 2
An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer
A Phase 2 study of Carcinoma, Non-Small-Cell Lung Cancer (NSCLC), sponsored by ToLymph.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
- 2
- Study locations
NCT06693336 is a Phase 2 study of Carcinoma, Non-Small-Cell Lung Cancer (NSCLC) that is actively recruiting participants, run by ToLymph. The registered enrollment target is 42 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT06693336, a Phase 2 study of Carcinoma, Non-Small-Cell Lung Cancer (NSCLC), is actively recruiting participants, sponsored by ToLymph.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study evaluates the use of SMS001 in patients with lung cancer. SMS001 is a new form of drug Paclitaxel. Doctors want to decide an appropriate safe dose for SMS001 administration, and to see how well it works in treating lung cancer patients.
Conditions Studied
Interventions
- DRUG SMS001
Study Locations (2)
Minnesota
- Mayo Clinic - Rochester
Ontario
- Toronto General Hospital - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2024-11-18 |
| Est. Completion | 2026-12-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06693336
The ClinicalTrials.gov registry entry for NCT06693336 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ToLymph, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Carcinoma, Non-Small-Cell Lung Cancer (NSCLC) appearing as the primary indexed condition, and to 1 intervention - of which SMS001 is the first listed.
NCT06693336 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Minnesota, Ontario.
Frequently Asked Questions
What is clinical trial NCT06693336 about?
NCT06693336 is a clinical study titled "An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer". This study evaluates the use of SMS001 in patients with lung cancer. SMS001 is a new form of drug Paclitaxel. Doctors want to decide an appropriate safe dose for SMS001 administration, and to see how well it works in treating lung cancer patients.
What is the current status of trial NCT06693336?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2024-11-18. Estimated completion is 2026-12-30.
What conditions does trial NCT06693336 study?
This clinical trial studies the following conditions: Carcinoma, Non-Small-Cell Lung Cancer (NSCLC).
What interventions are being tested in trial NCT06693336?
The interventions under investigation include: SMS001 (DRUG).
Who is sponsoring clinical trial NCT06693336?
This trial is sponsored by ToLymph, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06693336 being conducted?
This trial has 2 study locations across Minnesota, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.